[1]
|
Karagiannis TC, Lobachevsky PN, Martin RF. Cytotoxicity of an 125I-labelled DNA ligand. Acta Oncol, 2000, 39(6):681-685. |
[2]
|
Elmroth K, Stenerlöw B. DNA-incorporated 125I induces more than one double-strand break per decay in mammalian cells. Radial Res, 2005, 163(4):369-373. |
[3]
|
Casado FJ, Lostao MP, Aymerich I, et al. Nucleoside transporters in absorptive epithelia. J Physiol Biochem, 2002, 58(4):207-216. |
[4]
|
Bucheggter F, Vieira JM, Blaeuenstein P, et al. Preclinical Auger an gamma radiation dosimetry for lluorodeoxyuridine-enhanced turnout proliferation scintigraphy with [123I]iododeoxyuridine. Eur J Null Med Mol Imaging, 2003, 30(2):239-246. |
[5]
|
Taverna P, Hwang HS, Sehupp JE, et al. Inhibition of base exeision repair potentiates iododeoxyurdine-induced cytotoxicity and radiosensitization. Cancer Res, 2003, 63(4):838-846. |
[6]
|
Zackrisson B, Flvgare P. Gustafsson It, et al. Cell kinetic changes in human squamous cell carcinomas fluring radiotherapy studies using the the in vivo administration of two halogenated pyrimidines. Eur J Cancer, 2002, 38(8):1100-1106. |
[7]
|
Schneiderman MH, Schneiderman GS. Radioiododeoxyuridine in cancer therapy:an in vitro approach to developing in vivo strategies. J Nucl Med, 1996, 37(4 suppl):6S-9S. |
[8]
|
Baranowska-Kortylewicz J, Dalrymple GV, Harrison KA, et al. On tile safety of 5-[125I]iodo-2'-deoxyuridine-preclinical evaluation in swine. Acta Oncol. 1996, 35(7):925-933. |
[9]
|
Kassis AI, Adelstein SJ. Preclinical animal studies with radioiododeoxyuridine. J Nucl Med, 1996,374(suppl):10S-12S. |
[10]
|
Van den Abbeete AD, Tutrone RF, Berman RM, et al. Tumortargeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med, 1996, 37(2):315-320. |
[11]
|
Seo Y, Yan T, Schupp JE, et al. Differential radiosensitization in DNA mismatch repair-proficient and-deficient human colon cancer xenograits with 5-iodo-2-pyrimidinone-2'-deoxyribose. Clin Cancer Res, 2004, 10(22):7520-7528. |
[12]
|
Ou XH, Kuang AR, Peng X, et al. Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy. World J Gastroenterol, 2003, 9(8):1675-1678. |
[13]
|
Harrington K J, Syrigos KN, Uster PS, et al. Targeted radiosensitisation by pegylated liposome-encapsalated 3', 5'-O-dipalmitoyl5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model. Br J Cancer, 2004, 91(2):366-373. |
[14]
|
Kassis AI, Kirichian AM, Wang K, et al. Therapeutic potential of 5-[125I]iodo-2'-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int J Radiat Biol, 2004, 80(11-12):941-946. |
[15]
|
Okunieff P, Meyn RE, Teicher BA, et al. Report from the radiation oncology conunittee of the southwest oncology group (SWOG):research objectives workshop 2003. Am J Clin Oncol, 2003, 26(5):522-529. |
[16]
|
Harrison KA, Dahymple GV, Baranowskd-kortylewicz J, et al. Radiolabeled iododeoxyuridine:safety evaluation. J Nucl Med, 1996, 37(4 suppl):13S-16S. |
[17]
|
Mariani C, Cullecchi P, Baldassarri S, et al. Tumor uptake and mitotic activity pattern of 5-[125I]Iodo-2'-deoxyuridinc after intravesical in patients with bladder cancer. J Nucl Med, 1996, 37(4 suppl):16S-19S. |
[18]
|
Chiou RK, Dalrymple GV, Baranowska-Kortylewicz J, et al. Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer. J Urol, 1999, 162(1):58-62. |